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Review Article
Animal Remnant Kidney Model of
Chronic Renal Failure Revisited
Kai-Ming Chow,1,2 Zun-Chang Liu,1 Thomas Ming-Swi Chang1
Animal models have been the mainstay of experimental means to study chronic renal failure. An ideal
experimental animal model provides a stable uremic milieu to allow experimental manipulation. The model
should be technically simple to produce and have a reproducible degree of glomerular filtration rate reduction.
There should also be close mimicry of human chronic renal failure without additional (unwanted) physiologic
changes. This review article outlines the various choices of animal models in relation to the aforementioned
criteria, with particular emphasis on their advantages and shortcomings. In principle, reduction of renal mass
is undertaken in these models, after which adaptive changes take place in the remaining/remnant kidney. The
glomerular changes, in proportion to the number of nephrons resected or damaged, are characterized by growth
as well as hyperfunction. To date, the five-sixths nephrectomy model has remained the state-of-the-art prototype,
although it must be acknowledged that no single animal model can ever duplicate the original condition of
human kidney disease. It is in this context that a thorough understanding of each animal model allows the most
effective modeling strategy in biomedical research. Insofar as the ideal animal model does not exist, researchers
should use the biologic and biochemical diversity among the models to experimental advantage. It is expected,
with good reason, that the differences can tell us as much as the similarities. Attention to selection of appropriate
animal models is important to further advance the nephrology research frontier. [Hong Kong J Nephrol 2003;
5(2):57–64]
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INTRODUCTION
Our understanding of chronic renal failure and its
complications have been made possible by means of
experimental animal models, mostly in the rat. A wide
range of experimental (dietary and pharmacologic)
therapies explored in such models have also proven to
be clinically efficacious. Numerous methods, albeit not
well standardized, are available for inducing the model
of chronic renal failure and each has been strictly
defined in a given animal species. None of them can
ever duplicate the original condition in a human kidney.
Rather, it is the purpose of this review article to outline
the characteristics of each model, with special emphasis
on their individual advantages and drawbacks.
CHARACTERIZING AN ANIMAL MODEL
The term “animal model” in the sense of biomedical
research refers to a simplified representation of a more
complex system, with the hope that the information thus
obtained can be transferred to a more complex system.
The ideal experimental uremic model should constitute
a reproducible research environment that is similar to
human chronic renal failure, thus bridging the gap
between the artificial environment of an in vitro system
on the one hand and the complicated in vivo milieu of
the human on the other. Preferably, the animals should
be maintained in stable chronic renal failure for
relatively long periods of time for experiments of long-
term design. To illustrate these criteria in animal model
selection, a total nephrectomy model (an anephric
model) would not qualify as an ideal long-term model
because the animals would survive for less than 72
hours without dialysis support. Remnant kidney
models, induced in one way or another, provide an
acceptable animal survival rate but with less
reproducibility (in terms of the degree of uremia).
Furthermore, the model should, theoretically, be free
of additional pathophysiologic processes; ligation of
the ureter as a means of inducing experimental uremia
would be confounded by the elements of acute renal
failure and immune response [1,2], for example.
Three main ways of inducing experimental uremia
are categorized in the Figure. Among these models,
reduction of the renal mass by surgery is the most
common technique chosen.
SURGICAL FIVE-SIXTHS NEPHRECTOMY
Czerny performed the first human partial nephrectomy
in 1887 [3], in which the renal capsule was peeled back
for the area to be resected. Two years later, the first
animal partial nephrectomy was performed by Tuffier
[4], who removed one kidney and a portion of the
contralateral one thereafter. No changes in the
elimination of water or urea were demonstrated. In
1899, removing three-quarters of the canine renal mass
was attempted by Bradford, resulting in polyuria and
wasting [5]. In 1905, Heinecke carried out unilateral
nephrectomy and resection of one-half of the other
kidney [6]. Up to six additional resections had to be
performed in order to reduce the amount of
hypertrophied renal mass. Over the subsequent years,
Figure. Classification of various animal models for chronic renal failure.
Animal models of chronic renal failure
Surgical five-sixths Vascular ligation Chemical nephrectomy
nephrectomy methods (substance to produce renal damage)
Unilateral Unilateral renal Unilateral Interruption of
subtotal cortex destruction papillectomy blood supply to Nephrotoxin Immune reactive
nephrectomy with electro- with a major part of agents
with coagulation contralateral the renal
contralateral or cryosurgery nephrectomy parenchyma
nephrectomy with
contralateral
nephrectomy
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kidney resections were further attempted in cats, rabbits,
sheep and goats [7,8].
In 1932, Chanutin and Ferris first showed that
removal of five-sixths of the renal mass caused rats to
become uremic and to remain so for a prolonged period
of time [9]. In the pioneer two-step surgical procedure,
which became known as the five-sixths nephrectomy,
the upper and lower poles of the left kidney were ligated
and resected under ether anesthesia, leaving one-third
of the renal parenchyma and renal hilum intact. In some
cases, the ligated poles were left in situ. One to two
weeks later, a right nephrectomy was performed. Rats
made uremic in this manner were thereafter utilized as
models for studying chronic renal failure. Initial surgical
mortality was considerable, with a quoted success rate
of six animals surviving out of the 100 undergoing five-
sixths nephrectomy [10]. Platt et al further revised the
procedure in 1952, in which resection of the left kidney
poles (without ligation) was performed, followed by
unilateral right nephrectomy 10 to 14 days later [11].
Bleeding from the cut surfaces was controlled by digital
pressure at that time. With subsequent modifications
to the original technique, the animal model produced
by two-step nephrectomy herein described is now the
standard for five-sixths nephrectomy [12–14]. Proposed
revisions included intraoperative hemostasis maneuvers
(wrapping the remaining remnant of the kidney in
hemostatic gauze or application of thrombin solution
to the cut surfaces) and postoperative physiologic saline
supplementation. In addition, our group has refined the
technique to further minimize blood loss. Temporary
occlusion of the renal artery during the resection of the
upper and lower poles of the left kidney is achieved by
tying a thread around the renal pedicle. Bleeding is,
thus, considerably reduced.
By and large, the same principles of surgery have
been applied to other animal species, despite minor
revisions [15,16]. Simultaneous partial nephrectomy
and contralateral nephrectomy can be performed under
the same anesthetic for larger-sized animals. To obviate
the need for a second surgery, anecdotal evidence
suggests the feasibility of injecting absolute alcohol into
the renal artery of dogs instead of contralateral surgical
nephrectomy [17].
The structural and functional adaptive changes, after
acute reduction of the renal mass, represent the
pathologic processes of the remnant kidney model,
consistent with the intact nephron hypothesis [18]. After
significant reduction of the renal volume or nephron
number, compensatory renal hypertrophy occurs in the
remaining (remnant) kidney. The notion of renal
compensation had been entertained as early as 1869,
when the first human nephrectomy was planned by
Gustav Simon, who uninephrectomized dogs and
observed a 1.5-fold increase in the size of the remaining
kidney after 20 days [19,20]. In 1929, Verney described
“a very remarkable phenomenon” in his lecture – “the
remaining half (after functional renal mass reduction
by tying the renal artery branch of a dog kidney)
suddenly and without a moment’s hesitation doubled
its previous rate of secretion” [21]. Previous
experiments also showed that the remaining mouse
kidney becomes visibly engorged immediately after
uninephrectomy, whereas the rat glomeruli become
distinctly hyperemic within 1 minute [22]. This
adaptation is characterized by disproportionate
dilatation of glomerular afferent arterioles contributing
to an increase in single-nephron glomerular plasma flow
(hyperperfusion) and filtration (hyperfiltration) [18,20,
23]. Increasing excretory workload of the remaining
pool of normal nephrons characterizes the progressive
renal injury and disease of chronic renal failure. By
virtue of micropuncture techniques, single nephron
glomerular filtration rates measured within the remnant
kidney increased uniformly, the magnitude of which
closely correlated with the amount of renal mass being
resected [18,24]. These changes occur in conjunction
with glomerular capillary hypertension and tuft
enlargement. Various degrees of sclerosis (ranging from
focal segmental glomerulosclerosis to global
glomerulosclerosis), glomerulomegaly (increase in
glomerular volume compared to sham-operated
animals), mesangial expansion, and interstitial fibrosis
with tubular atrophy are well documented in remnant
kidney pathology after five-sixths nephrectomy in rats
[25–27]. Regeneration in mammalian kidneys does not
involve the development of new nephrons. De novo
nephron neogenesis in response to renal injury, on the
other hand, occurs in fish species including goldfish,
zebrafish, catfish, trout, tilapia, skate and aglomerular
toadfish. This fish nephron neogenesis model [28,29],
which may help to identify novel genes involved in
nephrogenesis and even has potential to develop
alternative renal replacement therapies, is beyond the
scope of this review.
One problem with the contemporary mammalian
five-sixths nephrectomy model has been the variable
degree of glomerular/renal injury. In general, removal
of the renal mass is expected to cause a significant
decrease in the glomerular filtration rate of rats, and
achieve a steady level around 2 weeks after unilateral
nephrectomy. The degree of uremia thus achieved,
nevertheless, was reported to be highly variable. The
possibility of inducing standardized and stable uremia
at predetermined levels would make the five-sixths
nephrectomy model more attractive. Our experience
and data from others [30] invariably demonstrated the
critical importance of minimizing the error margin in
assessing the amount of residual renal tissue or remnant
mass. Simply put, the main reason for the variable
glomerular filtration rates attained has been the failure
to appreciate the extent of the compensatory renal
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response by the remaining renal tissue. Meticulous
resection of the kidney poles (under direct vision) in
order to standardize the amount of remnant mass left
behind is the key to model reproducibility.
Alternatively, renal mass ablation by specially
designed diathermy or electrocautery probe has been
employed [31–34], although at a higher cost. Compared
to surgical resection, better hemostasis was achieved
this way. Electrocoagulation, on the other hand,
damages the residual tissue underlying the cortical burn
to a certain extent. Histopathology after the ablative
procedure might not, therefore, represent the
progressive injury that is seen in a diminished pool of
initially normal nephrons, as is the case with the intact
nephron hypothesis. Reproducibility of this model is
less satisfactory compared to surgical resection [35],
which is easy to understand with the reasoning outlined
before. Only the area of destroyed cortex can be defined
by means of electrocoagulation (despite standardization
of the current intensity and length of probe contact),
whereas the number of nephrons left behind is still
variable. A corollary of the electrocautery method is
the application of cryosurgery to reduce renal mass [36],
which might be less expensive. Again, the method itself
entails the additional mechanism of (potentially
undesirable) immunologic renal injury. In particular,
circulating antibodies against renal extracts and
immunoglobulin G deposits along the glomerular
basement membrane and in the mesangium were
demonstrated in animals after renal cryoablation [37].
A cautionary note, however, on the design of the
almost century-old five-sixths nephrectomy model is
that the original idea was to simulate progressive kidney
disease (such as that seen in chronic hypertension,
diabetes or other sclerosing processes) in the absence
of immunologic injury. Nevertheless, the current belief
is that any chronic progressive renal failure has an
immunologic/inflammatory component. This is
supported by the recent body of in vivo experimental
evidence regarding the efficacy of mycophenolate
mofetil on the progression of five-sixths nephrectomy-
related progressive renal failure [38–40]. Recruitment
of inflammatory cells is being recognized irrespective
of the initial renal insult, and even in experimental
models of a “non-immunologic” nature. Macrophage
infiltration, for example, was demonstrated shortly after
renal mass reduction in rats subjected to five-sixths
nephrectomy [40].
There is also legitimate concern that most renal
diseases in humans are not characterized by a sudden
decrease in the functioning renal mass, as mandated
by the current surgical model. Stated another way, more
gradual loss of renal mass might, intuitively, mimic
more closely the natural history of progressive renal
disease. Recently, a modification of the original
remnant kidney model has been proposed, with respect
to gradual renal ablation. Briefly, it involves an initial
left heminephrectomy (removal of the upper and lower
poles of the left kidney), followed by removing the
remainder of the left kidney 3 weeks later, and
subsequent right heminephrectomy another 3 weeks
later [41]. Higher albuminuria and increased focal
segmental glomerulosclerosis were demonstrated in this
gradual renal ablation model, compared to the
conventional five-sixths nephrectomy method. This
novel remnant kidney model merits further evaluation,
inasmuch as it extends the potential of the contemporary
five-sixths nephrectomy model.
VASCULAR LIGATION METHOD
Selective ligation of the renal arteries provides an
alternative method of inducing experimental uremia.
Briefly, unilateral (right) nephrectomy is combined with
ligation of most of the primary and secondary divisions
of the main left renal artery. The degree of renal
infarction is assessed by discoloration (for example,
75% of the kidney) and, hence, is interpreted as
ischemia that progresses to infarction. Segmental
infarction of the contralateral kidney is, thus, achieved
[42–45]. According to our experience in small-sized
animals [46–49], the prolonged operative time with
microsurgery and variation in the degree of uremia
achieved are disadvantageous.
Our previous evaluation of surgical resection
compared to vascular infarction methods, for example,
showed a consistent degree of glomerular filtration rate
reduction in the former, resulting in 20% to 30% of
normal creatinine clearance in Wistar rats. This
compared favorably with the wide-ranging creatinine
clearance (0.3% to 74% of normal) from the infarction
model. In particular, the standard deviation of blood
urea nitrogen in the surgical resection model was
substantially lower than that derived from the infarction
model [46]. The feasibility of achieving a reproducible
chronic renal failure model by vascular ligation, even
in the case of larger animals, is also compromised by
the formation of collateral vessels that bypass the
ligated branches and the inconsistent ramification
pattern of the renal artery [50]. In accord with our
experience in rat models, the ligation technique induced
a much less consistent degree of azotemia than did the
surgical resection technique of five-sixths nephrectomy
in canine models [16,50].
The following caveats should be understood in light
of the uncertainty induced by vascular ligation. Renal
ablation by compromising the vascular supply might
induce an element of renovascular hypertension, as
occurs in the classical Goldblatt model. Propensity for
hypertension in such models that leave infarcted renal
tissue in situ has often been a concern because the
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presence of systemic hypertension greatly influences
the progression of the experimental model. In the
presence of severe systemic hypertension, for example,
glomerulosclerosis was documented in rats after limited
(40%) nephrectomy only [51]. More recently,
additional injury mechanisms induced by the vascular
ligation method, as opposed to conventional surgical
renal ablation, have been reaffirmed. Such evidence
comes from the studies comparing surgical renal mass
reduction with models of vascular ligation [52–54].
With an equivalent reduction in renal mass, the uremic
animals in the vascular ligation model demonstrated
significant proteinuria and glomerulosclerosis that were
not seen in surgical mass reduction models. Glomerular
capillary hypertension was also considerably higher in
the case of renal infarction [53]. In addition to the
mixture of systemic hypertension in the remnant kidney
model, increased deposition of immunoglobulins was
demonstrated in the remaining kidney, as derived from
experimental infarction [55], thus implying an
additional element of immunologically mediated injury.
Of note, the contributory role of immunologic factors
in the vascular ligation renal infarction model was
suggested [55] when the disease process was prevented
by the administration of cortisone or 6-mercaptopurine.
In view of the burgeoning interest in uremic models
of various animals, it is worth emphasizing that studies
of vascular ligation have not always demonstrated the
same degree, or even type of abnormalities, as
evidenced in most studies using rats [56,57]. The
pathology of the rabbit vascular ligation model, for
example, is predominantly tubulo-interstitial
nephropathy as characterized by hypercalcemia,
hypercalciuria and urinary stones, but minimal
glomerular scarring [58]. Likewise, proteinuria is
modest and arterial hypertension is inconsistent despite
the presence of glomerular sclerosis in the dog model
of uremia induced by vascular ligation [59–61]. Despite
the proteinuria and histologic glomerular alterations,
dogs might have preserved renal function for up to 4
years after renal infarction [61]. The vascular ligation
model applied to cats yields all of the features seen in
the rat model, including hypertension, proteinuria and
glomerular sclerosis [62,63]. Certain strains of mice
demonstrate none of the characteristic pathophysiology
of the rat model [57]. In a similar manner, genetic
factors of susceptibility to glomerulosclerosis and
disease progression operate in the rat, depending on
the strain being studied [26,64,65]. As a general rule,
Wistar, Sprague-Dawley and Lewis rats are commonly
chosen for the uremic animal models, based on their
propensity to develop progressive, age-related
glomerular lesions. In addition, within the rat model
itself, the nature and extent of compensatory renal
growth depends, to a great extent, on their age at the
time of renal ablation [26,66,67]. Hypertrophy
predominates in adults, whereas less compensatory
growth occurs in old rats. This highlights the potential
pitfalls in extrapolating information gathered from one
particular animal model to another, which could be as
erroneous as directly transferring lessons from animal
to human conditions.
CHEMICAL NEPHRECTOMY
Another way to induce experimental renal failure is
via the administration of nephrotoxic chemical agents.
Among them, parenteral use of uranyl nitrate,
adriamycin or adenine ingestion has been evaluated for
inducing renal damage [7,68–70]. The disadvantage is
clear. Biologic or pathologic effects of these chemical
agents on the lymphoid and other organ systems would
be difficult to monitor and control. Demonstration of
anemia in laboratory animals, for example, gives rise
to a diagnostic conundrum. Does it indicate the sequelae
of uremia or the effects of the agent on hematopoiesis?
Likewise, most of the immunologic models of kidney
failure [71,72] lead to nephrotic syndrome or specific
glomerular disease which, in many ways, alters
nutrition, amino acid and protein metabolism.
Moreover, immunologic and toxic experimental
models seldom represent stable and far advanced renal
failure. Animal susceptibility to nephrotoxins also
varies. For example, the nephrotoxic threshold of the
human kidney to aminoglycoside antibiotics is
significantly lower than that of laboratory animals, and
this threshold even varies among different strains (and
ages) of rats [73,74]. Given the substantial inter-
individual variation in the dose response curve for most
of these chemical agents, their effects in individual
animals are difficult to predict. The diverse actions of
these agents are also recognized, as illustrated by the
classic example of adriamycin, which induces
proteinuria (resembling minimal change nephropathy
in humans) by glomerular damage in rats after a single
intravenous injection [75], whereas serial injections lead
to chronic progressive renal failure [69].
FROM ANIMAL TO HUMAN: BENCH TO BEDSIDE
It becomes obvious from this review that the variety of
animal models behave in different ways. The question
therefore arises: how good are they at shedding light
on our understanding of human chronic renal failure?
In particular, previous therapeutic successes in rats
failed to demonstrate the expected response in humans
with progressive renal disease [76].
Notwithstanding the practical advantages of using
animal models for experimental purposes, there is little
doubt that numerous differences exist between them
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and humans. Several of these differences deserve
attention. First and foremost, direct comparisons of
animal remnant kidney models with human kidneys
with similar nephron mass losses are lacking. If any,
the degree of reduction in renal mass in humans (such
as with unilateral nephrectomy or transplant donation)
is relatively modest compared with the ablation or five-
sixths nephrectomy model in animals [56]. Second,
animal experimentation typically involves a small
number of rodents of a given gender and age, all of
them being subjected to a uniform procedure such as
standardized five-sixths nephrectomy. This represents
a distinctly homogenous cohort of animals with
comparable renal injury, in contradiction to clinical
trials enrolling subjects with wide-ranging age, blood
pressure, nephropathy etiology and rate of disease
progression. End points are more tangible in rodents
because they progress to end-stage renal failure over a
relatively short period of time, i.e. in terms of several
months as opposed to a decade or more in humans.
Secondary end points such as serial renal histology are,
again, never practical in the clinical scenario. A third
obvious problem is the timing of intervention. The
experimental animal uremic model allows timely
introduction of dietary or pharmacologic intervention
shortly after renal insult, a convenience not often
encountered in our practical daily care of chronic kidney
disease patients.
To learn the most from animal models, it is
noteworthy to emphasize that there is, as yet, no
experimental equivalent of human chronic renal failure
disease. With these perspectives in mind, the differences
can, perhaps, tell us as much as the similarities.
CONCLUSIONS
Most established animal models of chronic renal failure
bear some similarities to clinical chronic renal failure,
but none is fully representative and ideal (Table).
Regardless of the animal model and animal species,
the criteria for an acceptable experimental uremic
model are that it: (i) is appropriate as an analog of
human kidney disease in the broad sense and,
preferably, has a standardized degree of uremia;
(ii) provides the ease and amenability to experimental
manipulation; (iii) is specific to chronic renal failure
without other concomitant disease processes; and
(iv) has an excellent track record with established
biologic properties including morphology (renal
pathology) and functional (laboratory) data.
By and large, renal mass reduction is thought to
closely resemble human kidney disease in which an
initial insult causes loss of a selected population of
functioning nephrons, leading to functional and
metabolic alterations in the remnant “intact” nephrons.
While there has been little dispute about the time-
honored five-sixths nephrectomy as the prototype
model for renal failure, the essential question always
arises as to whether or not, or to what extent, we can
extrapolate the chosen model to the human kidney and
disease process being studied.
To summarize, the odysseys of experimental animal
models are epitomized by the remarks of Dr. Peter
Kennedy [77], “No one should expect to find a perfect
animal model but ... there is still much to learn from
very close corollaries.”
REFERENCES
1. Rodrigues LE, Martinelli RP, Cruz I, Rocha H. Effect of acute
experimental uremia on the stability of liver lysosomal
membranes. Nephron 1977;18:88–92.
2. Schreiner GF, Harris KP, Purkerson ML, Klahr S. Immunological
aspects of acute ureteral obstruction: immune cell infiltrate in the
kidney. Kidney Int 1988;34:487–93.
3. Goldstein AE, Abeshouse BS. Partial resection of the kidney:
report of 6 cases and review of literature. J Urol 1937;38:15–42.
4. Pearce RM. The influence of the reduction of kidney substance
upon nitrogenous metabolism. J Exper Med 1908;10:632–44.  [In
French]
5. Bradford JR. The results following partial nephrectomy and the
influence of the kidney on metabolism. J Physiol 1899;23:415–
96.
6. Heinecke P. Trials on the pathology of  Morbus Brightii. Verh
Dtsch Ges Pathol 1905;9:99–117. [In German]
7. Allen FM, Scharf R, Lundin H. Clinical and experimental renal
deficiency. JAMA 1925;85:1698–701.
8. Strauch M, Gretz N. Animal models to induce renal failure: a
historical survey. Contrib Nephrol 1988;60:1–8.
9. Chanutin A, Ferris EB. Experimental renal insufficiency produced
Table. Comparison of currently available animal models of chronic renal failure.
Ease of Reproducibility Devoid of Similarity to human
application additional effects chronic renal failure
Surgical 5/6 nephrectomy * ** *** **
Nephrectomy plus electrocautery ** * ** **
Vascular ligation method ** * * *
Chemical method ** * * *
Desirability of individual model denoted by * (least desirable) to *** (most desirable), varies with animal species being applied.
Hong Kong J Nephrol • October 2003 • Vol 5 • No 2 63
Animal uremic models
by partial nephrectomy. Arch Intern Med 1932;49:767–87.
10. Griffith JQ, Jeffers WA. The circulation system. In: Farris EJ,
Griffith JQ, eds. Rat in Laboratory Investigation. Philadelphia:
JB Lippincott, 1949;291–300.
11. Platt R, Roscoe MH, Wemyss-Smith F. Experimental renal failure.
Clin Sci 1952;11:217–31.
12. Morrison AB. Experimentally induced chronic renal insufficiency
in the rat. Lab Invest 1962;11:321–32.
13. Waynforth HB, Flecknell PA. Nephrectomy. In: Waynforth HB,
Flecknell PA, eds. Experimental and Surgical Technique in the
Rat, 2nd ed. London: Academic Press, 1992;274–5.
14. Gretz N, Waldherr R, Strauch M. The remnant kidney model.
In: Gretz N, Strauch M, eds. Experimental and Genetic Rat
Models of Chronic Renal Failure. Basel: S. Karger Publishing,
1993;1–28.
15. McKenna PH, Khoury AE, McLorie GA, Reid G, Churchill BM.
A surgical model for normotensive chronic renal failure in the
growing piglet. J Urol 1992;148:756–9.
16. Brassard JA, Meyers KM, Person M, Dhein CR. Experimentally
induced renal failure in the dog as an animal model of uremic
bleeding. J Lab Clin Med 1994;124:48–54.
17. Fine A, Jones D, Kaushal G, LeGal Y, Sharma G. Remnant model
of renal failure in the dog: avoidance of second surgery by
chemical nephrectomy. Clin Invest Med 1990;13:152–4.
18. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner
BM. Hyperfiltration in remnant nephrons: a potentially adverse
response to renal ablation. J Am Soc Nephrol 2001;12:1315–25.
19. Peters G. Introduction: history and problems of compensatory
adaptation of renal functions and of compensatory hypertrophy
of the kidney. Yale J Biol Med 1978;51:235–45.
20. Fine L. The biology of renal hypertrophy. Kidney Int 1986;
29:619–34.
21. Verney EB. Experimental reduction of renal tissue. Lancet 1929;
1:645–51.
22. Malt RA. Compensatory growth of the kidney. N Engl J Med 1969;
280:1446–59.
23. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of
glomerular hypertension limits glomerular injury in rats with
reduced renal mass. J Clin Invest 1985;76:612–9.
24. Yoshida Y, Fogo A, Shiraga H, Glick AD, Ichikawa I. Serial
micropuncture analysis of single nephron function in subtotal
renal ablation. Kidney Int 1988;33:855–67.
25. Shimamura T, Morrison AB. A progressive glomerulosclerosis
occurring in partial five-sixths nephrectomized rats. Am J Pathol
1975;79:95–106.
26. Waldherr R, Gretz N. Natural course of the development of
histological lesions after 5/6 nephrectomy. Contrib Nephrol
1988;60:64–72.
27. Faraj AH, Morley AR. Remnant kidney pathology after five-sixth
nephrectomy in rat: I. A biochemical and morphological study.
APMIS 1992;100:1097–105.
28. Reimschussel R. A fish model of renal regeneration and
development. ILAR J 2001;42:285–91.
29. Elger M, Hentschel H, Litteral J, Wellner M, Kirsch T, Luft FC,
et al. Nephrogenesis is induced by partial nephrectomy in the
elasmobranch Leucoraja erinacea. J Am Soc Nephrol 2003;
14:1506–18.
30. Ormrod D, Miller T. Experimental uraemia: description of a model
producing varying degrees of stable uremia. Nephron 1980;26:
249–54.
31. Boudet J, Man NK, Pils P, Sausse A, Funck-Brentano JL.
Experimental chronic renal failure in the rat by electrocoagulation
of the renal cortex. Kidney Int 1978;14:82–6.
32. Gibb IA, Hamilton DN. An experimental model of chronic renal
failure in mice. Clin Immunol Immunopathol 1985;35:276–84.
33. Gagnon RF, Ansari M. Development and progression of uremic
changes in the mouse with surgically induced renal failure.
Nephron 1990;54:70–6.
34. Gonzalez EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM,
Sampath TK, et al. Treatment of a murine model of high-turnover
renal osteodystrophy by exogenous BMP-7. Kidney Int 2002;61:
1322–31.
35. Gretz N, Meisinger E, Strauch M. Experimental models to assess
the influence of low protein diets on the progression of chronic
renal failure. Contrib Nephrol 1986;53:7–20.
36. Kumano K, Kogure K, Tanaka T, Sakai T. A new method of
inducing experimental chronic renal failure by cryosurgery. Kidney
Int 1986;30:433–6.
37. Kanetake H. Cryoimmunologic investigations of the rabbit kidney.
Invest Urol 1977;14:373–7.
38. Fujihara CK, Malheiros DM, Zatz R, Noronha ID. Mycophenolate
mofetil attenuates renal injury in the rat remnant kidney. Kidney
Int 1998;54:1510–9.
39. Romero F, Rodríguez-Iturbe B, Parra G, González L, Herrera-
Acosta J, Tapia E. Mycophenolate mofetil prevents the progressive
renal failure induced by 5/6 renal ablation in rats. Kidney Int
1999;55:945–55.
40. Noronha IL, Fujihara CK, Zatz R. The inflammatory component
in progressive renal disease – are interventions possible? Nephrol
Dial Transplant 2001;17:363–8.
41. Kim KH, Kim Y, Park HW, Jeong HJ, Mauer M. A re-evaluation
of the renal ablation model of progressive renal disease in rats.
J Nephrol 2003;16:196–202.
42. Eschbach JW, Adamson JW, Dennis MB. Physiologic studies in
normal and uremic sheep: I. The experimental model. Kidney Int
1980;18:725–31.
43. Avioli LV, Scott S, Lee SW. Intestinal calcium absorption: nature
of defect in chronic renal disease. Science 1969;166:1154–6.
44. Al Banchaabouchi M, Marescau B, D’Hooge R, Van Marck E,
Van Daele A, Levillain O, et al. Biochemical and histopathological
changes in nephrectomized mice. Metabolism 1998;47:355–61.
45. Shapiro RJ. Catabolism of low-density lipoprotein is altered in
experimental chronic renal failure. Metabolism 1993;42:162–9.
46. Liu ZC, Chow KM, Chang TM. Evaluation of two protocols of
uremic rat model: partial nephrectomy and infarction. Ren Fail
2003 (in press).
47. Prakash S, Chang TM. Microencapsulated genetically engineered
live E. coli DH5 cells administered orally to maintain normal
plasma urea level in uremic rats. Nat Med 1996;2:883–7.
48. Prakash S, Chang TM. In vitro and in vivo uric acid lowering by
artificial cells containing microencapsulated genetically
engineered E. coli DH5 cells. Int J Artif Organs 2000;23:429–35.
49. Prakash S, Chang TM. Artificial cells microencapsulated
genetically engineered E. coli DH5 cells for the lowering of plasma
creatinine in vitro and in vivo. Artif Cells Blood Substit Immobil
Biotechnol 2000;28:397–408.
50. Vaneerdeweg W, Buyssens N, De Winne T, Sebrechts M, Babloyan
A, Arakelian S, et al. A standardized surgical technique to obtain
a stable and reproducible chronic renal failure model in dogs.
Eur Surg Res 1992;24:273–82.
51. Meyer TW, Rennke HG. Progressive glomerular injury after limited
renal infarction in the rat. Am J Physiol 1988;254:F856–62.
K.M. Chow, et al
64 Hong Kong J Nephrol • October 2003 • Vol 5 • No 2
52. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction
is a critical modulator of subsequent hypertension and glomerular
injury. J Am Soc Nephrol 1994;4:2023–31.
53. Griffin KA, Picken MM, Churchill M, Churchill P, Bidani AK.
Functional and structural correlates of glomerulosclerosis after
renal mass reduction in the rat. J Am Soc Nephrol 2000;11:
497–506.
54. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA,
Dunea G. Effect of relaxin in two models of renal mass reduction.
Am J Nephrol 2003;23:8–12.
55. White FN, Grollman A. Autoimmune factors associated with
infarction of the kidney. Nephron 1964;1:93–102.
56. Hostetter TH. Progressive renal disease: is the slippery slope
species specific? J Lab Clin Med 1987;109:375–7.
57. Kren S, Hostetter TH. The course of the remnant kidney model in
mice. Kidney Int 1999;56:333–7.
58. Eddy AA, Falk RJ, Sibley RK, Hostetter TH. Subtotal nephrectomy
in the rabbit: a model of chronic hypercalcemia, nephrolithiasis,
and obstructive nephropathy. J Lab Clin Med 1986;107:508–16.
59. Polzin DJ, Leininger JR, Osborne CA, Jeraj K. Development of
renal lesions in dogs after 11/12 reduction of renal mass. Influences
of dietary protein intake. Lab Invest 1988;58:172–83.
60. Bourgoignie JJ, Gavellas G, Martinez E, Pardo V. Glomerular
function and morphology after renal mass reduction in dogs.
J Lab Clin Med 1987;109:380–8.
61. Brown SA, Finco DR, Crowell WA, Choat DC, Navar LG. Single-
nephron adaptations to partial renal ablation in the dog. Am J
Physiol 1990;258(3 pt 2):F495–503.
62. Adams LG, Polzin DJ, Osborne CA, O’Brien TD, Hostetter TH. Influence
of dietary protein/calorie intake on renal morphology and function in cats
with 5/6 nephrectomy. Lab Invest 1994;70:347–57.
63. Brown SA, Brown CA. Single-nephron adaptations to partial renal
ablation in cats. Am J Physiol 1995;269:R1002–8.
64. Weening JJ, Beukers JJ, Grond J, Elema JD. Genetic factors in
focal segmental glomerulosclerosis. Kidney Int 1986;29:789–98.
65. Westenend PJ, Grond J, Weening JJ. Strain and species differences
in experimental models of progressive glomerulosclerosis. In:
Gretz N, Strauch M, eds. Experimental and Genetic Rat Models
of Chronic Renal Failure. Basel: S. Karger Publishing, 1993;
236–49.
66. Hayslett JP. Effect of age on compensatory renal growth. Kidney
Int 1983;23:599–602.
67. Wesson LG. Compensatory growth and other growth responses
of the kidney. Nephron 1989;51:149–84.
68. Fukuda S, Kopple JD. Chronic uremia syndrome in dogs induced
with uranyl nitrate. Nephron 1980;25:139–43.
69. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M.
Adriamycin-induced nephropathy as a model of chronic
progressive glomerular disease. Kidney Int 1986;29:502–10.
70. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal models of adenine-
induced chronic renal failure in rats. Nephron 1986;44:230–4.
71. Klassen J, Sugisaki T, Milgrans F, McCluskey RT. Studies on
multiple renal lesions in Heymann nephritis. Lab Invest 1971;25:
577–85.
72. Allison ME, Wilson CB, Gottschalk CW. Pathophysiology of
experimental glomerulonephritis in rats. J Clin Invest 1974;53:
1402–23.
73. Falco FG, Smith HM, Arcieri  GM. Nephrotoxicity of
aminoglycosides and gentamicin. J Infect Dis 1969;119:406–9.
74. Hierholzer K. Value and necessity of animal research in
nephrology. In: Gärtner K, Stolte H, Hackbarth H, eds. Research
Animals and Concepts of Applicability to Clinical Medicine.
Basel: S. Karger Publishing, 1982;88–101.
75. Remuzzi G, Zoja C, Remuzzi A, Rossini M, Battaglia C, Broggini
M, et al. Low-protein diet prevents glomerular damage in
adriamycin-treated rats. Kidney Int 1985;28:21–7.
76. El Nahas AM. Glomerular sclerosis: from rat to man. Ren Fail
1993;15:385–8.
77. Davidson MK, Lindsey JR, Davis JK. Requirements and selection
of an animal model. Isr J Med Sci 1987;23:551–5.
